Design TherapeuticsDSGN
Market Cap: 297M
About: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Employees: 57
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
47% more capital invested
Capital invested by funds: $84M [Q4 2023] → $124M (+$39.8M) [Q1 2024]
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
6% more funds holding
Funds holding: 88 [Q4 2023] → 93 (+5) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]
2.24% less ownership
Funds ownership: 56.64% [Q4 2023] → 54.39% (-2.24%) [Q1 2024]
43% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 37
78% less call options, than puts
Call options by funds: $4K | Put options by funds: $18K
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
Piper Sandler Yasmeen Rahimi | 129%upside $12 | Overweight Upgraded | 7 May 2024 |
RBC Capital Leonid Timashev | 24%downside $4 | Sector Perform Reiterated | 20 Mar 2024 |
Wedbush Laura Chico | 5%downside $5 | Neutral Reiterated | 20 Mar 2024 |